|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Desai JR, Ochoa S, Prins PA and He AR:
Systemic therapy for advanced hepatocellular carcinoma: An update.
J Gastrointest Oncol. 8:243–255. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pascual S, Herrera I and Irurzun J: New
advances in hepatocellular carcinoma. World J Hepatol. 8:421–438.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ahmed I and Lobo DN: Malignant tumours of
the liver. Surgery (Oxford). 25:34–41. 2007. View Article : Google Scholar
|
|
5
|
Hiyama E: Pediatric hepatoblastoma:
Diagnosis and treatment. Transl Pediatr. 3:293–299. 2014.PubMed/NCBI
|
|
6
|
Trobaugh-Lotrario AD and Katzenstein HM:
Chemotherapeutic approaches for newly diagnosed hepatoblastoma:
Past, present, and future strategies. Pediatr Blood Cancer.
59:809–812. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khaderi S, Guiteau J, Cotton RT, O'Mahony
C, Rana A and Goss JA: Role of liver transplantation in the
management of hepatoblastoma in the pediatric population. World J
Transplant. 4:294–298. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Villanueva A, Hernandez-Gea V and Llovet
JM: Medical therapies for hepatocellular carcinoma: A critical view
of the evidence. Nat Rev Gastroenterol Hepatol. 10:34–42. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Trobaugh-Lotrario AD, Meyers RL, O'Neill
AF and Feusner JH: Unresectable hepatoblastoma: Current
perspectives. Hepat Med. 9:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bober J and Samek P: Surgery of the
tumours of the liver. Bratisl Lek Listy. 103:403–407.
2002.PubMed/NCBI
|
|
11
|
Horiike N, Iuchi H, Ninomiya T, Kawai K,
Kumagi T, Michitaka K, Masumoto T and Onji M: Influencing factors
for recurrence of hepatocellular carcinoma treated with
radiofrequency ablation. Oncol Rep. 9:1059–1062. 2002.PubMed/NCBI
|
|
12
|
Shinohara M, Mirakaj V and Serhan CN:
Functional metabolomics reveals novel active products in the DHA
metabolome. Front Immunol. 3:812012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duvall MG and Levy BD: DHA- and
EPA-derived resolvins, protectins, and maresins in airway
inflammation. Eur J Pharmacol. 785:144–155. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Serhan CN, Chiang N, Dalli J and Levy BD:
Lipid mediators in the resolution of inflammation. Cold Spring Harb
Perspect Biol. 7:a0163112014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen X, Gong X, Jiang R, Wang B, Kuang G,
Li K and Wan J: Resolvin D1 attenuates CCl4-induced acute liver
injury involving up-regulation of HO-1 in mice. Immunopharmacol
Immunotoxicol. 38:61–67. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kuang H, Hua X, Zhou J and Yang R:
Resolvin D1 and E1 alleviate the progress of hepatitis toward liver
cancer in long-term concanavalin A-induced mice through inhibition
of NF-κB activity. Oncol Rep. 35:307–317. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kang J and Lee S: Resolvin D1 protects the
liver from ischemia/reperfusion injury by enhancing M2 macrophage
polarization and efferocytosis. Biochim Biophys Acta.
1861:1025–1035. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Palmer CD, Mancuso CJ, Weiss JP, Serhan
CN, Guinan EC and Levy O: 17(R)-Resolvin D1 differentially
regulates TLR4-mediated responses of primary human macrophages to
purified LPS and live E. coli. J Leukoc Biol. 90:459–470. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao Q, Wu J, Lin Z, Hua Q, Zhang W, Ye L,
Wu G, Du J, Xia J, Chu M and Hu X: Resolvin D1 alleviates the lung
ischemia reperfusion injury via complement, immunoglobulin, TLR4
and inflammatory factors in rats. Inflammation. 39:1319–1333. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang S and Liu G: Targeting the
Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett.
13:1041–1047. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mao J, Yang J, Zhang Y, Li T, Wang C, Xu
L, Hu Q, Wang X, Jiang S, Nie X and Chen G: Arsenic trioxide
mediates HAPI microglia inflammatory response and subsequent neuron
apoptosis through p38/JNK MAPK/STAT3 pathway. Toxicol Appl
Pharmacol. 303:79–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baig MS, Liu D, Muthu K, Roy A, Saqib U,
Naim A, Faisal SM, Srivastava M and Saluja R: Heterotrimeric
complex of p38 MAPK, PKCδ, and TIRAP is required for AP1 mediated
inflammatory response. Int Immunopharmacol. 48:211–218. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang Q, Liu X, Wu Y, Liao Y, Huang Y, Wei
X and Ma M: P38 MAPK pathway mediates cognitive damage in
pentylenetetrazole-induced epilepsy via apoptosis cascade. Epilepsy
Res. 133:89–92. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abdelmoaty S, Wigerblad G, Bas DB,
Codeluppi S, Fernandez-Zafra T, El-Awady el-S, Moustafa Y,
Abdelhamid Ael-D, Brodin E and Svensson CI: Spinal actions of
lipoxin A4 and 17(R)-resolvin D1 attenuate inflammation-induced
mechanical hypersensitivity and spinal TNF release. PLoS One.
8:e755432013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hossein R, Reza A, Mehdi H and Akram M:
The effect of extracted bacterial LPS from Salmonella enteritidis
on COX-2 in hepg2 cell line in induction and inhibition conditions.
Sci Res Essays. 6:5771–5775. 2011.
|
|
26
|
Xie W, Wang H, Liu Q, Li Y, Wang J, Yao S
and Wu Q: ResolvinD1 reduces apoptosis and inflammation in primary
human alveolar epithelial type 2 cells. Lab Invest. 96:526–536.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Recchiuti A: Resolvin D1 and its GPCRs in
resolution circuits of inflammation. Prostaglandins Other Lipid
Mediat. 107:64–76. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Casper C and Fitzmaurice C:
Infection-related cancers: Prioritising an important and eliminable
contributor to the global cancer burden. Lancet Glob Health.
4:e580–e581. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tang F, Wang Y, Hemmings BA, Rüegg C and
Xue G: PKB/Akt-dependent regulation of inflammation in cancer.
Semin Cancer Biol. May 2–2017.(Epub ahead of print).
|
|
31
|
Kumar S, Chan CJ and Coussens LM:
Inflammation and cancer. Encyclopedia of Immunobiology.
420:406–415. 2016. View Article : Google Scholar
|
|
32
|
Suganuma M, Okabe S, Kurusu M, Iida N,
Ohshima S, Saeki Y, Kishimoto T and Fujiki H: Discrete roles of
cytokines, TNF-alpha, IL-1, IL-6 in tumor promotion and cell
transformation. Int J Oncol. 20:131–136. 2002.PubMed/NCBI
|
|
33
|
Kuninaka S, Yano T, Yokoyama H, Fukuyama
Y, Terazaki Y, Uehara T, Kanematsu T, Asoh H and Ichinose Y: Direct
influences of pro-inflammatory cytokines (IL-1beta, TNF-alpha,
IL-6) on the proliferation and cell-surface antigen expression of
cancer cells. Cytokine. 12:8–11. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Patel HJ and Patel BM: TNF-α and cancer
cachexia: Molecular insights and clinical implications. Life Sci.
170:56–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Piccioli P and Rubartelli A: The secretion
of IL-1β and options for release. Semin Immunol. 25:425–429. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Feigerlová E and Battaglia-Hsu SF: IL-6
signaling in diabetic nephropathy: From pathophysiology to
therapeutic perspectives. Cytokine Growth Factor Rev. 37:57–65.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zanke BW, Boudreau K, Rubie E, Winnett E,
Tibbles LA, Zon L, Kyriakis J, Liu FF and Woodgett JR: The
stress-activated protein kinase pathway mediates cell death
following injury induced by cis-platinum, UV irradiation or heat.
Curr Biol. 6:606–613. 1996. View Article : Google Scholar : PubMed/NCBI
|
